NCT06663787 2026-04-13
HER2 CR
Nagoya City University
Active not recruiting
Clinical Trials
5 trialsNCT05081609 2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2 Active not recruiting
NCT04784715 2026-02-20
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT00393783 2025-06-05
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting